Do LDLR loss-of-function and PCSK9 gain-of-function variants raise LDL cholesterol and apolipoprotein B?

Genetic variants affecting the low-density lipoprotein receptor (LDLR) and proprotein convertase subtilisin/kexin type 9 (PCSK9) are primary determinants of individual lipid profiles and cardiovascular risk.

Mechanistic explanations

• LDLR activity and hepatic clearance: The low-density lipoprotein receptor (LDLR) on the surface of hepatocytes is the primary pathway for removing circulating apoB-100-containing low-density lipoprotein (LDL) particles. Loss-of-function variants in the LDLR gene directly reduce receptor expression or activity, which severely lowers the fractional catabolic rate (clearance) of LDL particles. Consequently, the circulating residence time of LDL is prolonged, driving up serum LDL cholesterol (LDL-C) and apolipoprotein B (apoB) levels.
• PCSK9-mediated receptor degradation: PCSK9 regulates LDLR density by binding to the receptor's extracellular domain and targeting it for lysosomal degradation rather than recycling. Gain-of-function (GOF) mutations in PCSK9 (such as the D374Y variant) significantly increase its binding affinity to LDLR. This accelerates receptor degradation, leading to a marked depletion of functional hepatic LDLRs and impaired LDL clearance.
• Apolipoprotein B production pathways: Beyond clearance, LDLR is involved in the presecretory degradation of nascent apoB within the hepatocyte secretory pathway. Reduced LDLR function or its accelerated degradation by PCSK9 GOF variants can decrease this intracellular degradation, thereby increasing the hepatic assembly and secretion of VLDL and other apoB-containing lipoproteins into the circulation.

Clinical evidence

• Familial Hypercholesterolemia (FH): Severe loss-of-function mutations in LDLR or gain-of-function mutations in PCSK9 cause autosomal-dominant FH. Patients with these variants exhibit profoundly elevated LDL-C (often >190 mg/dL in heterozygotes and >500 mg/dL in homozygotes) and highly elevated apoB concentrations.
• Opposing genetic phenotypes: In contrast, loss-of-function PCSK9 variants (such as R46L) reduce LDLR degradation, maintaining high levels of hepatic receptors. Individuals carrying these protective variants exhibit significantly lower LDL-C levels (typically a 15–30% reduction) and a dramatic, lifelong reduction in coronary heart disease risk.

Bottom line

Genetic variants that reduce LDLR activity or increase PCSK9 function directly impair the hepatic clearance of LDL particles from the bloodstream. This physiological block, compounded by enhanced hepatic secretion of apoB-containing lipoproteins, leads to profound and sustained elevations in circulating LDL cholesterol and apolipoprotein B, significantly increasing cardiovascular risk.